Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 261 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Orthovisc Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition

NCT03712137
View directory record Official record
Conditions
Jawline Definition
Interventions
VOLUX XC, No-treatment control
Device · Other
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Rosa, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Phase 2 Interventional

Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)

NCT00993707
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CTX-100 (formerly ETX-100) (hyaluronic acid)
Drug
Lead sponsor
Turino, Gerard, M.D.
Individual
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 21, 2026, 1:15 PM EDT
Recruiting Phase 1 Interventional

Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies

NCT07292818
View directory record Official record
Conditions
Cervix Cancer
Interventions
Barrigel gel spacer
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone

NCT01186835
View directory record Official record
Conditions
Forehead/Glabellar Rhytid Complexes
Interventions
Combination Botulinum Toxin A and Hyaluronic Acid, Botulinum Toxin A
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies

NCT03700047
View directory record Official record
Conditions
Cheek Augmentation
Interventions
GAL1704, Juvederm Voluma
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
15
States / cities
Los Angeles, California • Sacramento, California • Solana Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Ethnic Lip Augmentation With Hyaluronic Acid Filler

NCT05730543
View directory record Official record
Conditions
Lip Augmentation, Lip Fullness
Interventions
Volbella or Juvederm Ultra XC filler
Drug
Lead sponsor
DeNova Research
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 21, 2026, 1:15 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Slit Face Trial Using Micro-injections of Transparent Hyaluronic Acid Gel for Rejuvenation of the Cheek

NCT02679924
View directory record Official record
Conditions
Problem of Aging
Interventions
Hyaluronic Acid filler, Sham Comparator
Device · Other
Lead sponsor
Isabella Guiha
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

NCT02176356
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
Interventions
onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC
Biological · Drug · Device
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Efficacy of a Proprietary "Joint Health" Dietary Supplement in Subjects With Joint and Connective Tissue Pain

NCT03209895
View directory record Official record
Conditions
Joint Pain
Interventions
Joint Health Product, Placebo, Glucosamine / Chondroitin
Dietary Supplement
Lead sponsor
U.S. Nutraceuticals, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Sausalito, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation

NCT01197495
View directory record Official record
Conditions
Lip Augmentation
Interventions
hyaluronic acid gel
Device
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 21, 2026, 1:15 PM EDT
Recruiting Early Phase 1 Interventional

HA35 Moderate Alcoholic Hepatitis (AH) Study

NCT05018481
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Sodium Hyaluronate, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Phase 4 Interventional

Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne

NCT05446402
View directory record Official record
Conditions
Acne
Interventions
Geologie Acne Regimen - one side of face, Proactive Acne Regimen - other side of face
Combination Product
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

NCT05932732
View directory record Official record
Conditions
Cutis Laxa Facialis, Xeroderma
Interventions
HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System
Device · Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
30 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

NCT04262336
View directory record Official record
Conditions
Ototoxicity
Interventions
DB-020, Placebo
Drug
Lead sponsor
Decibel Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Miami, Florida • Kansas City, Kansas • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 21, 2026, 1:15 PM EDT
Terminated Phase 3 Interventional Results available

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

NCT02715804
View directory record Official record
Conditions
Pancreatic Ductal Carcinoma
Interventions
Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo, nab-Paclitaxel, Gemcitabine
Other · Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
64
States / cities
Mobile, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 21, 2026, 1:15 PM EDT
Terminated Not applicable Interventional

Retrobulbar Injection of Anesthesia Versus Healon 5 in the Management of Intraoperative Floppy Iris Syndrome

NCT00627913
View directory record Official record
Conditions
Intraoperative Floppy Iris Syndrome
Interventions
Healon 5 injection, Retrobulbar anesthetic injection
Procedure
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Perioral Rejuvenation and Upper Lip Enhancement

NCT03273543
View directory record Official record
Conditions
Perioral Rejuvenation, Upper Lip Projection
Interventions
Restylane® Defyne
Device
Lead sponsor
DeNova Research
Other
Eligibility
21 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 21, 2026, 1:15 PM EDT
Terminated Phase 1 Interventional

Pilot Study of Therapy With Hylan G-F 20 Exercise Capacity

NCT01810848
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Hylan G-F 20, Control
Device · Other
Lead sponsor
OhioHealth
Other
Eligibility
40 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 21, 2026, 1:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

NCT02753595
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Whittier, California • Atlanta, Georgia • Newnan, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI

NCT00922623
View directory record Official record
Conditions
Facial Wrinkles
Interventions
Belotero®
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Los Angeles, California • Mitchellville, Maryland • Montclair, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hyaluronic Acid Filler for Dorsal Finger Volume Loss

NCT02793739
View directory record Official record
Conditions
Personal Satisfaction
Interventions
Hyaluronic acid filler injection
Procedure
Lead sponsor
Marmur Medical
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 21, 2026, 1:15 PM EDT
Recruiting Not applicable Interventional

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

NCT06496256
View directory record Official record
Conditions
Prostate Cancer
Interventions
Barrigel, Transrectal Ultrasound
Device
Lead sponsor
Palette Life Sciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Chandler, Arizona • Santa Barbara, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 1:15 PM EDT
Completed Not applicable Interventional Results available

Effectiveness Trial for Evaluating IAHA for PFPS

NCT01811654
View directory record Official record
Conditions
Patellofemoral Pain Syndrome
Interventions
Intra-Articular Hyaluronic Acid-Euflexxa
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 21, 2026, 1:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722
View directory record Official record
Conditions
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
Interventions
EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
Drug
Lead sponsor
enGene, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 21, 2026, 1:15 PM EDT